Back to Search
Start Over
In vivo Metabolic Profiles as Determined by 31 P and short TE 1 H MR-Spectroscopy : No Difference Between Patients with IDH Wildtype and IDH Mutant Gliomas.
- Source :
-
Clinical neuroradiology [Clin Neuroradiol] 2019 Mar; Vol. 29 (1), pp. 27-36. Date of Electronic Publication: 2017 Oct 05. - Publication Year :
- 2019
-
Abstract
- Purpose: Previous ex vivo spectroscopic data from tissue samples revealed differences in phospholipid metabolites between isocitrate dehydrogenase mutated (IDHmut) and IDH wildtype (IDHwt) gliomas. We investigated whether these changes can be found in vivo using <superscript>1</superscript> H-decoupled <superscript>31</superscript> P magnetic resonance spectroscopic imaging (MRSI) with 3D chemical shift imaging (CSI) at 3 T in patients with low and high-grade gliomas.<br />Methods: The study included 33 prospectively enrolled, mostly untreated patients who met spectral quality criteria according to the World Health Organization (WHO II n = 7, WHO III n = 17, WHO IV n = 9; 25 patients IDHmut, 8 patients IDHwt). The MRSI protocol included <superscript>1</superscript> H decoupled <superscript>31</superscript> P MRSI with 3D CSI (3D <superscript>31</superscript> P CSI), 2D <superscript>1</superscript> H CSI and a  <superscript>1</superscript> H single voxel spectroscopy sequence (TE 30 ms) from the tumor area. For <superscript>1</superscript> H MRS, absolute metabolite concentration values were calculated (phantom replacement method). For <superscript>31</superscript> P MRS, metabolite intensity ratios were calculated for the choline (C) and ethanolamine (E)-containing metabolites.<br />Results: In our patient cohort we did not find significant differences for the ratio of phosphocholine (PC) and phosphoethanolamine (PE), PC/PE, (p = 0.24) for IDHmut compared to IDHwt gliomas. Furthermore, we found no elevated ratios of glycerophosphocholine (GPC) and glycerophosphoethanolamine (GPE), GPC/GPE, (p = 0.68) or GPC/PE (p = 0.12) for IDHmut gliomas. Even the ratio (PC+GPC)/(PE+GPE) showed no significant differences with respect to mutation status (p = 0.16). Nonetheless, changes related to tumor grade regarding intracellular pH (pH <subscript>i</subscript> ) and phospholipid metabolism as well as absolute metabolite concentrations of co-registered 2D <superscript>1</superscript> H CSI data for tumor and control tissue showed the anticipated results.<br />Conclusion: Using 3D-CSI data acquisition, in vivo <superscript>31</superscript> P MR spectroscopic measurement of phospholipid metabolites could not distinguish between IDHmut and IDHwt.
- Subjects :
- Adult
Aged
Analysis of Variance
Astrocytoma enzymology
Astrocytoma genetics
Astrocytoma pathology
Astrocytoma therapy
Biomarkers, Tumor metabolism
Brain Neoplasms genetics
Brain Neoplasms pathology
Brain Neoplasms therapy
Diagnosis, Differential
Ethanolamines analysis
Ethanolamines metabolism
Female
Glioblastoma enzymology
Glioblastoma genetics
Glioblastoma pathology
Glioblastoma therapy
Glioma genetics
Glioma pathology
Glioma therapy
Glutarates analysis
Glutarates metabolism
Glycerylphosphorylcholine analysis
Humans
Hydrogen
Isocitrate Dehydrogenase metabolism
Isoenzymes analysis
Isoenzymes metabolism
Male
Middle Aged
Mutation
Neoplasm Grading
Oligodendroglioma enzymology
Oligodendroglioma genetics
Oligodendroglioma pathology
Oligodendroglioma therapy
Phosphatidylethanolamines analysis
Phosphatidylethanolamines metabolism
Phosphorus Isotopes
Phosphorylcholine analysis
Phosphorylcholine metabolism
Prospective Studies
Tumor Burden
Biomarkers, Tumor genetics
Brain Neoplasms metabolism
Glioma metabolism
Isocitrate Dehydrogenase genetics
Magnetic Resonance Spectroscopy methods
Subjects
Details
- Language :
- English
- ISSN :
- 1869-1447
- Volume :
- 29
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Clinical neuroradiology
- Publication Type :
- Academic Journal
- Accession number :
- 28983683
- Full Text :
- https://doi.org/10.1007/s00062-017-0630-8